P and T最新文献

筛选
英文 中文
Droxidopa for Hypotension of Different Etiologies: Two Case Reports. 羟多巴治疗不同病因性低血压2例报告。
P and T Pub Date : 2019-03-01
Jomi Oommen, Judy Chen, Shan Wang, Thomas Caraccio, Adel Hanna
{"title":"Droxidopa for Hypotension of Different Etiologies: Two Case Reports.","authors":"Jomi Oommen,&nbsp;Judy Chen,&nbsp;Shan Wang,&nbsp;Thomas Caraccio,&nbsp;Adel Hanna","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Orthostatic hypotension is defined as a decrease in systolic blood pressure of at least 20 mmHg or a decrease in diastolic blood pressure of at least 10 mmHg (or both), within three minutes of moving from a supine to an upright or standing position. Droxidopa is a synthetic amino acid analog that is directly metabolized to norepinephrine by dopa-decarboxylase, subsequently providing alpha and beta-agonist effects to increase blood pressure. It is indicated in the treatment of neurogenic orthostatic hypotension caused by primary autonomic failure that is associated with Parkinson disease, multi-system atrophy, pure autonomic failure, dopamine beta-hydroxylase deficiency, and/or non-diabetic autonomic neuropathy. In addition, it has been studied in other disease states, such as diabetic autonomic neuropathy-associated orthostatic hypotension and supine hypotension. We report on two cases of off-label droxidopa use. The first case was for diabetic autonomic neuropathy-associated orthostatic hypotension, and the second case was for hypotension due to autonomic dysfunction associated with rheumatoid arthritis. Although the outcomes differed in each case, this article contributes to the literature demonstrating that droxidopa may have varying effects in treating orthostatic hypotension of non-neurogenic etiology.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"125-144"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385736/pdf/ptj4403125.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37019427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research Briefs. 研究简报。
P and T Pub Date : 2019-03-01
{"title":"Research Briefs.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"145-147"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385737/pdf/ptj4403145.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37019430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Routine Use of Vitamin K in the Treatment of Cirrhosis-Related Coagulopathy: Is it A-O-K? Maybe Not, We Say. 常规使用维生素K治疗肝硬化相关凝血病:是A-O-K吗?也许不是,我们说。
P and T Pub Date : 2019-03-01
Sarah M Aldrich, Randolph E Regal
{"title":"Routine Use of Vitamin K in the Treatment of Cirrhosis-Related Coagulopathy: Is it A-O-K? Maybe Not, We Say.","authors":"Sarah M Aldrich,&nbsp;Randolph E Regal","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Historically, coagulopathy related to cirrhosis has been managed primarily as a bleeding disorder. However, several recent studies have shown that patients with cirrhosis have an increased risk of both bleeding and clotting. These coagulopathic changes are a result of the decreased synthetic capabilities of the cirrhotic liver. Vitamin K is often given to correct prolonged prothrombin times (PT) in patients with cirrhosis. However, this practice is not well defined and its effectiveness is questionable. The objective of our literature review is to determine the effectiveness of vitamin K to correct coagulopathy in cirrhosis. This report evaluates data published between 1981 and 2017. Published articles relevant to vitamin K use in cirrhotic patients were reviewed and summarized. The available literature regarding the use of vitamin K in cirrhosis is limited, and the research published so far does not appear to support its use. The routine uses of vitamin K to correct PT/international normalized ratio in hepatic cirrhosis should be avoided unless further studies can demonstrate true clinical benefit.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"131-136"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385738/pdf/ptj4403131.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37019428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paralyzed by Mistakes - Reassess the Safety of Neuromuscular Blockers in Your Facility. 因错误而瘫痪--重新评估设备中神经肌肉阻断剂的安全性。
P and T Pub Date : 2019-03-01
Matthew Grissinger
{"title":"Paralyzed by Mistakes - Reassess the Safety of Neuromuscular Blockers in Your Facility.","authors":"Matthew Grissinger","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Neuromuscular blockers have been inadvertently administered to patients who were not receiving proper ventilatory assistance, causing death or permanent injuries.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"91-107"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385733/pdf/ptj4403091.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37193737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Forensic Analysis in Drug Litigation Finds Most Errors Occur with Commonly Used Therapies and Practices. 药物诉讼中的法医分析发现,大多数错误发生在常用的治疗和实践中。
P and T Pub Date : 2019-03-01
James T O'Donnell, James J O'Donnell, F Randy Vogenberg
{"title":"Forensic Analysis in Drug Litigation Finds Most Errors Occur with Commonly Used Therapies and Practices.","authors":"James T O'Donnell,&nbsp;James J O'Donnell,&nbsp;F Randy Vogenberg","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In the complex setting of obstetrics and reproductive medicine, the medication-related injuries leading to the most litigation involve some of the most commonly used drugs, rather than the newer, more complicated therapies. The authors present a number of cases illustrating how sophisticated treatment of high-risk pregnancies can be jeopardized by a simple negligent act.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"118-121"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385734/pdf/ptj4403118.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37193746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Do GPOs Play a Role in Drug Shortages? Long-Standing Allegations Disputed by The GPOs. gpo在药品短缺中起作用吗?gpo对长期存在的指控提出异议。
P and T Pub Date : 2019-03-01
Stephen Barlas
{"title":"Do GPOs Play a Role in Drug Shortages? Long-Standing Allegations Disputed by The GPOs.","authors":"Stephen Barlas","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>What role, if any, do group purchasing organizations play in drug shortages?</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"94-121"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385730/pdf/ptj4403094.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37193739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug and Device News. 药品和器械新闻。
P and T Pub Date : 2019-03-01
{"title":"Drug and Device News.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Approvals, new indications and formulations, and safety issues.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"95-107"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385731/pdf/ptj4403095.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37193741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmaceutical Approval Update. 药品审批更新。
P and T Pub Date : 2019-03-01
Michele B Kaufman
{"title":"Pharmaceutical Approval Update.","authors":"Michele B Kaufman","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Inbrija (levodopa inhalation powder) for oral inhalation for the treatment of \"off\" episodes in Parkinson's disease; Ultomiris (ravulizumab) injection for treating adults with paroxysmal nocturnal hemoglobinuria; and Yupelri (revefenacin) inhalation solution for the maintenance treatment of patients with COPD.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"108-144"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385732/pdf/ptj4403108.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37193743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The 60th American Society of Hematology Annual Meeting & Exposition. 第60届美国血液学会年会暨博览会。
P and T Pub Date : 2019-03-01
Walter Alexander
{"title":"The 60th American Society of Hematology Annual Meeting & Exposition.","authors":"Walter Alexander","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We report on two presentations on β-thalassemia and myelodysplastic syndromes, three presentations on chronic lymphocytic leukemia, and others on perioperative oral anticoagulation, sickle-cell anemia, diffuse large B-cell lymphoma, and multiple myeloma.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"138-142"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385735/pdf/ptj4403138.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37019429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lowering the Boom on High Drug Prices: HHS Plans Not a Boon to Some Players. 降低高药价的繁荣:卫生与公众服务部的计划对一些玩家来说不是一个福音。
P and T Pub Date : 2019-03-01
Stephen Barlas
{"title":"Lowering the Boom on High Drug Prices: HHS Plans Not a Boon to Some Players.","authors":"Stephen Barlas","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The Trump administration's multipronged effort to use regulatory tools to lower drug prices includes old and new initiatives. But opposition from some players is evident in each instance. Some of that opposition may be based on sound reasoning, some of it may be based on self-interest. The author discusses advertising, protected-class drugs, what's next for rebates, and more.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"122-142"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385728/pdf/ptj4403122.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37193747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信